Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 28: 481-484, 1982;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welch, C. L.
Right arrow Articles by Moyer, T. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welch, C. L.
Right arrow Articles by Moyer, T. P.

Clinical Chemistry, Vol 28, 481-484, Copyright © 1982 by American Association for Clinical Chemistry

Liquid-chromatographic determination of zomepirac in serum and plasma

CL Welch, TM Annesley, HS Luthra and TP Moyer

We describe a determination of zomepirac concentration in plasma and serum by reversed-phase "high-performance" liquid chromatography. The assay requires 1.0 mL of sample and involves diethyl ether extraction of zomepirac from an acidified sample, followed by concentration and injection into a liquid chromatograph. The column effluent is monitored at 330 nm. Retention times of zomepirac and the internal standard (tolmetin) are 3.8 and 2.7 min, respectively. The lower limit of detection for zomepirac in serum or plasma is 0.05 mg/L. Within-day precision (CV) of analysis in plasma or serum with zomepirac added (0.1- 10.0 mg/L) ranged from 1.4 to 6.7%; between-day CV varied from 1.4 to 7.5%. Analytical recovery of zomepirac (1.0 mg/L) from serum and plasma was 77.6 (SD 3.5)% and 80.4 (SD 5.2)%, respectively. Numerous commonly coadministered drugs did not interfere. The elimination half-life of the drug was 1.8 h, and the peak plasma concentration ranged from 1.1 to 2.4 mg/L. Peak and trough concentrations measured throughout five days of therapy imply no accumulation.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by the American Association for Clinical Chemistry.